|
HER2-negative advanced breast cancer
|
STEMVAC
|
I
|
NCT02157051
|
|
HER2-negative advanced breast cancer
|
WOKVAC
|
I
|
NCT02780401
|
|
HER2- negative metastatic breast cancer with BRCA1 or BRCA2 mutation
|
MEDI4736 with Olaparib
|
I/II
|
NCT02734004
|
|
HER2-negative metastatic breast cancer
|
MEDI4736 with Tremelimumab
|
II
|
NCT02536794
|
|
HER2-negative metastatic breast cancer
|
Pembrolizumab+Aromatase Inhibitor
|
II
|
NCT02648477
|
|
HER2-negative metastatic breast cancer
|
Pembrolizumab and Nab-paclitaxel
|
II
|
NCT02752685
|
|
Recurrent HER2-negative metastatic breast cancer
|
Opdivo & Abraxane
|
I
|
NCT02309177
|
|
Advanced triple negative breast cancer
|
Pembrolizumab plus chemotherapy
|
I/II
|
NCT02331251
|
|
Advanced triple negative breast cancer
|
AM0010 (recombinant human IL-10)
|
I
|
NCT02009449
|
|
Advanced triple negative breast cancer
|
MEDI4736 with Olaparib or Cediranib
|
I/II
|
NCT02484404
|
|
Advanced triple negative breast cancer
|
MEDI4736 with Vigil
|
II/III
|
NCT02725489
|
|
Advanced triple negative breast cancer
|
PVX-410 Vaccine in combination with Durvalumab
|
I
|
NCT02826434
|
|
Advanced triple negative breast cancer
|
Entinostat and Nivolumab with or without Ipilimumab
|
I
|
NCT02453620
|
|
Advanced triple negative breast cancer
|
Tremelimumab
|
II
|
NCT02527434
|
|
Advanced triple negative breast cancer
|
Atezolizumab+Nab-Paclitaxel
|
II
|
NCT02425891
|
|
Advanced triple negative breast cancer
|
PDR001
|
I/II
|
NCT02404441
|
|
Metastatic triple-negative breast cancer
|
Pembrolizumab plus chemotherapy
|
I/II
|
NCT02734290
|
|
Metastatic triple-negative breast cancer
|
Halaven & Pembrolizumab
|
I/II
|
NCT02513472
|
|
Metastatic triple-negative breast cancer
|
Pembrolizumab with Carboplatin and Gemcitabine
|
II
|
NCT02755272
|
|
Metastatic triple-negative breast cancer
|
Pembrolizumab plus radiotherapy
|
II
|
NCT02730130
|
|
Metastatic triple-negative breast cancer
|
TAK-659 with Nivolumab
|
I
|
NCT02834247
|
|
Metastatic triple-negative breast cancer
|
CSF1R Inhibitor (PLX3397) with Pembrolizumab
|
I/II
|
NCT02452424
|
|
Metastatic triple-negative breast cancer
|
Single-dose Cyclophosphamide +Pembrolizumab
|
II
|
NCT02768701
|
|
Metastatic triple-negative breast cancer
|
Pembrolizumab
|
I
|
NCT02447003
|
|
Metastatic triple-negative breast cancer
|
Pembrolizumab
|
III
|
NCT02555657
|
|
Metastatic triple-negative breast cancer
|
Niraparib with Pembrolizumab
|
I/II
|
NCT02657889
|
|
Stage I-III triple negative breast cancer
|
MEDI4736 and chemotherapy before surgery
|
I/II
|
NCT02489448
|
|
HER2+ breast cancer
|
NeuVax with Herceptin
|
II
|
NCT01570036
|
|
HER2+ breast cancer
|
Atezolizumab with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab
|
I
|
NCT02605915
|
|
HER2+ advanced breast cancer
|
AdHER2/neu dendritic cell vaccine
|
I
|
NCT01730118
|
|
ER+, stage I, II or III breast cancer
|
MONTANIDE™ ISA 51 VG combined with neoadjuvant chemotherapy
|
I/II
|
NCT02229084
|
|
Metastatic breast cancer
|
Hypofractionated radiotherapy with MEDI4736 and Tremelimumab
|
I
|
NCT02639026
|
|
Persistent Triple-Negative Disease
|
Personalized polyepitope DNA vaccine following neoadjuvant chemotherapy
|
I
|
NCT02348320
|
